Clinical Evidence

Our clinical programs are leading the field

Explore the scientific evidence supporting GRAIL’s multi-cancer early detection approach, including peer-reviewed publications and presentations at leading medical congresses. Together, these data highlight test performance, clinical utility, and progress toward transforming cancer screening.

Jump to:

MANUSCRIPTS

PRESENTATIONS

Foundational data

Validation
CCGA

Case-control study

Annals of Oncology

Read Full Article
Clinical Performance
PATHFINDER 2

Prospective screening study

Nature Medicine

Read Full Article
Clinical Utility
NHS-Galleri

Randomized control study

Nature Medicine

Read Full Article
Performance in Medicare
Real-World Experience

Prospective real-world study

Nature Communications

Read Full Article

Featured evidence

Presentation

European Society for Medical 
Oncology (ESMO) 2025

Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study

See Presentation
Manuscript

JCO Precision Oncology

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes of Analysis

Read Full Article
Manuscript

Cancer Prevention Research

Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches

Read Full Article
Presentation

American Association of Cancer Research (AACR) 2026

Association Between Emergency Department (ED) Involvement in Cancer Diagnosis and Survival Across Cancer Types in the Medicare Population

See Presentation

Manuscripts

Lancet Oncology

Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data

February 16, 2026
View Manuscript
British Journal of Cancer

Modelled impact of a multi-cancer early detection screening programme on the demand for diagnostics in England

January 31, 2026
View Manuscript
JCO Precision Oncology

Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer\’s Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation

January 14, 2026
View Manuscript
eClinicalMedicine

Experience of NHS diagnostic investigation following a multi-cancer early detection (MCED) screening test: qualitative interviews with NHS-Galleri trial participants who had a cancer signal detected

January 8, 2026
View Manuscript
PharmacoEconomics - Open

Potential Economic Value of Multi‐cancer Early Detection Testing Under Differential Cost Trends for Cancer Screening and Management

December 23, 2025
View Manuscript
JCO Precision Oncology

Multicancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study

December 18, 2025
View Manuscript